Seyoung Jung

Seyoung Jung

Auto-generated profile, based on publicly available information

Seyoung Jung

Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, 34141, Republic of Korea

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HKHyung-Don Kim
Hyung-Don Kim
SJSeyoung Jung
Seyoung Jung
HLHo Yeong Lim
Ho Yeong Lim
BRBaek-Yeol Ryoo
Baek-Yeol Ryoo
MRMin-Hee Ryu
Min-Hee Ryu
CYChanghoon Yoo
Changhoon Yoo
Regorafenib has anti-tumor activity in patients with unresectable hepatocellular carcinoma (uHCC) with potential immunomodulatory effects, suggesting that its combination with immune checkpoint inhibitor may have clinically meaningful benefits in patients with uHCC. The multicenter, single-arm, phase 2 RENOBATE trial tested regorafenib–nivolumab as front-line treatment for uHCC. Forty-two patients received nivolumab 480 mg every 4 weeks and regorafenib 80 mg daily (3-weeks-on/1-week-off schedule). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The secondary endpoints included safety, progression-free survival (PFS) and overall survival (OS). ORR per RECIST version 1.1 was 31.0%, meeting the primary endpoint. The most common adverse events were palmar-plantar erythrodysesthesia syndrome (38.1%), alopecia (26.2%) and skin rash (23.8%). Median PFS was 7.38 months. The 1-year OS rate was 80.5%, and the median OS was not reached. Exploratory single-cell RNA sequencing analyses of peripheral blood mononuclear cells showed that long-term responders exhibited T cell receptor repertoire diversification, enrichment of genes representing immunotherapy responsiveness in MKI67+ proliferating CD8+ T cells and a higher probability of M1-directed monocyte polarization. Our data support further clinical development of the regorafenib–nivolumab combination as front-line treatment for uHCC and provide preliminary insights on immune biomarkers of response. ClinicalTrials.gov identifier: NCT04310709.

2 March 2023 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
SJSeyoung Jung
Seyoung Jung
JLJeong Seok Lee
Jeong Seok Lee
Seyoung Jung and Jeong Seok Lee. Mol. Cells 2023;46:120-9. https://doi.org/10.14348/molcells.2023.0002

19 September 2024 in EBioMedicine
Verified
Journal Article
Open access
SCSung Hae Chang
Sung Hae Chang
SJSeyoung Jung
Seyoung Jung
JCJeong Jun Chae
Jeong Jun Chae
JKJeong Yeon Kim
Jeong Yeon Kim
SKSeon Uk Kim
Seon Uk Kim
JLJeong Seok Lee
Jeong Seok Lee
Interstitial lung disease (ILD) poses a serious threat in patients with rheumatoid arthritis (RA). However, the impact of cornerstone drugs, including methotrexate (MTX) and TNF inhibitor, on RA-associated ILD (RA-ILD) remains controversial. Using an SKG mouse model and single-cell transcriptomics, we investigated the effects of MTX and TNF blockade on ILD. Our study revealed that MTX exacerbates pulmonary inflammation by promoting immune cell infiltration, Th17 activation, and fibrosis. In contrast, TNF inhibitor ameliorates these features and inhibits ILD progression. Analysis of data from a human RA-ILD cohort revealed that patients with ILD progression had persistently higher systemic inflammation than those without progression, particularly among the subgroup undergoing MTX treatment. These findings highlight the need for personalized therapeutic approaches in RA-ILD, given the divergent outcomes of MTX and TNF inhibitor. This work was funded by GENINUS Inc., and the National Research Foundation of Korea, and Seoul National University Hospital.

1 June 2023 in Journal of Korean Medicine
Verified
Journal Article
Open access
PDF file
SLSundong Lee
Sundong Lee
HKHyundo Kim
Hyundo Kim
SJSeyoung Jung
Seyoung Jung
Bo-In KwonBo-In Kwon
Bo-In Kwon
Objectives: To study symptom differentiation for yang deficiency and blood heat based on 117 psoriasis patients.Methods: Obtained frequency analysis (%), mean (%), and OR, CL(P-value) with prospective pre-post intervention design and multiple regression analysis.Results: There were no statistically significant differences as to sex, BMI, smoking and marital status, but there were statistically significant differences in variables of average age, gene history, and alcohol consumption (P<0.05). There were no statistically significant differences in psoriasis symptoms as to initial age of onset, morbidity span, area of the initial onset, and the progression of psoriasis during the last three months of each patient. However, the type of psoriasis showed a statistically significant difference (p=0.011). While there were no statistically significant differences as to common cold, condition of psoriasis after recovering from the cold, skin condition, exercise, and seasonality, irregular perspiration showed significant difference (p<0.00). When confounding factors have been controlled the blood heat patient group as the comparison group, multiple regression analysis showed OR, CI(95%) of 1.06(0.31-3.63) for men, 0.28(0.08-1.06) for aged 30 to 49,0 and 0.18(0.04-0.80) for aged 50 and older. it was 0.06(0.01-0.7) for gene history, 1.06(0.29-3.88) for drink alcohol, 19.90(2.53-156.7) for seasonality, and 10.28 (3.19-33.11) for perspiration problems. In these variables, Sex, age, smoking, and alcohol consumption showed no statistically significant results, but gene history(p=0.049), seasonality(p=0.005), and irregular perspiration (p=0.017) were statistically significant.Conclusion: Family history, seasonality and irregular perspiration are the determining factors for yang deficiency and blood heat in psoriasis.